Please assess the completion status of the following clinical trial:

Trial Title: Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Adults greater than or equal to 18 years of age upon entry into screening.~* Documented history of migraine (with or without aura) greater than or equal to 12 months prior to screening according to the International Classification of Headache Disorders-3rd Edition (ICHD-3).~* Greater than or equal to 4 and less than 15 days per month of migraine symptoms (based on ICHD-3 criteria) on average across 3 months prior to screening based on retrospective reporting.~* Less than 15 days per month of headache symptoms (i.e., migraine and non-migraine).~* Subjects in need for switching by documented failure of 1 or 2 prophylactic treatments in the last 6 months due to either lack of efficacy or poor tolerability. For subjects with 1 prior treatment failure, the failure should have occurred in the last 6 months. For subjects with 2 prior treatment failures, the second treatment failure should have occurred in the last 6 months.~* During baseline: Confirmed migraine frequency of 4 to 14 migraine days and less than 15 days of headache symptoms.~* During baseline: greater than or equal to 80% compliance with the headache diary.~Exclusion Criteria:~* Subjects meeting any of the following criteria are not eligible for inclusion in this study.~  * Older than 50 years of age at migraine onset.~ * History of cluster headache or hemiplegic migraine headache.~ * Unable to differentiate migraine from other headaches.~ * Lack of efficacy or poor tolerability with greater than 2 treatments from the 7 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial.~* Efficacy failure is defined as no meaningful reduction in headache frequency, duration, and/or severity after administration of the medication for at least 6 weeks at the generally accepted therapeutic dose(s) based on the investigator's assessment.~* Tolerability failure is defined as documented discontinuation due to adverse events of the respective medication during the last 6 months prior to screening.~* The following scenarios do not constitute lack of therapeutic response:~* Lack of sustained response to a medication.~* Patient decision to halt treatment due to improvement.~* Used a prohibited medication from the 7 categories of prior prophylactic medications within 3 months prior to the start of and during baseline for a non-migraine indication if dose is not stable~* Exposure to botulinum toxin in the head and/or neck region within 4 months.~* Taken the following for any indication in any month during the 2 months prior to the start of the baseline period:~  * Ergotamines or triptans on greater than or equal to 10 days per month, or Simple analgesics (non-steroidal anti-inflammatory drugs \[NSAIDs\], acetaminophen) on greater than or equal to 15 days per month, or~ * Opioid- or butalbital-containing analgesics on greater than or equal to 4 days per month.~* Device, or procedure that potentially may interfere with the intensity or number of migraine days within 2 months prior to the start of or during baseline.~* History of major psychiatric disorders (such as schizophrenia or bipolar disorder) or current evidence of depression. Subjects with anxiety disorder and/or major depressive disorders are permitted in the study if they are considered by the investigator to be stable and are taking no more than 1 medication for each disorder. Subjects must have been on a stable dose within the 3 months prior to the start of the baseline period.~* History of seizure disorder or other significant neurological conditions other than migraine. Note: a single childhood febrile seizure is not exclusionary.~* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Human immunodeficiency virus (HIV) infection by history.~* History or evidence of any other unstable or clinically significant medical condition or clinically significant vital sign, laboratory, or electrocardiogram (ECG) abnormality during that could pose a risk to subject safety or interfere with the study evaluation.~* Myocardial infarction, stroke, transient ischemic attack, unstable angina, or coronary artery bypass surgery or other re-vascularization procedures within 6 months prior to screening.~* Score yes on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or yes on any item of the Suicidal Behavior section, except for the Non-Suicidal Self-Injurious Behavior (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.~* Evidence of drug or alcohol abuse or dependence, based on Investigator discretion within 12 months.~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential must use contraception during dosing with study treatment.~* Use of other investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.~* History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.~* Previous exposure to AMG334 or exposure to any other prophylactic CGRP-targeted therapy (prior to the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG334 70 mg/140 mg (Type: EXPERIMENTAL): Participants were randomized to receive 70 mg or 140 mg of AMG334 as a subcutaneous injection once per month for 52 weeks in the Core Phase.~Participants were permitted to switch to an approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study.
- Oral Prophylactic (Type: ACTIVE_COMPARATOR): Participants were randomized to receive a standard of care (SOC) locally approved oral prophylactic migraine medication once per day for 52 weeks in the Core Phase, as prescribed per local country labels.~Participants were permitted to switch to a different approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).